Increasing Prevalence Of Chronic Diseases Boosts Growth Prospects For The Exocrine Pancreatic Insufficiency (EPI) Market: An Emerging Driver Transforming The Exocrine Pancreatic Insufficiency Market Landscape

The Exocrine Pancreatic Insufficiency Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Exocrine Pancreatic Insufficiency Market?
In recent times, the market size for exocrine pancreatic insufficiency has experienced robust growth. Expected to rise from $2.59 billion in 2024 to $2.76 billion in 2025, it boasts a compound annual growth rate (CAGR) of 6.6%. The historic period's growth is credited to heightened awareness and diagnostic procedures, an increase in digestive disorders, an aging demographic, pancreatic function reduction, and a surge in gastrointestinal surgeries.

The market for exocrine pancreatic insufficiency is poised for robust expansion in the coming years, predicted to reach a worth of $3.58 billion by 2029, rising at a compounded annual growth rate (CAGR) of 6.7%. The market's growth projection during the forecast period can be linked to factors like increasing awareness and screening processes, an aging population, an upsurge in chronic diseases, and enhancements in patient healthcare accessibility and digestive health research and development. The forecast period also anticipates trends like digital health and telehealth solutions, cooperative research programs, emphasis on pediatric epi strategies, regulatory progress and accelerated approval procedures, market growth in emerging economies, and progress in healthcare infrastructure.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13107

What Are the Different Exocrine Pancreatic Insufficiency Market Segments?
The exocrine pancreatic insufficiency market covered in this report is segmented -

1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types
3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Specialty Clinics, Homecare

Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules, Non-Enteric-Coated Capsules, Powder Formulations
3) By Other Treatments: Medications, Surgical Interventions, Supportive Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13107&type=smp

What Are the Primary Drivers Shaping the Exocrine Pancreatic Insufficiency Market?
The escalation of chronic diseases is anticipated to spur the expansion of the exocrine pancreatic insufficiency market. Chronic diseases, defined as longer-lasting medical problems that extend over a substantial period, generally more than three months, can potentially increase the risk of secondary health complications such as exocrine pancreatic insufficiency. This situation prompts a more efficient management of chronic diseases through various medical strategies and treatments, allowing individuals suffering from these conditions to lead longer lives. For example, the World Health Organization, the United Nations' specialized agency headquartered in Switzerland, reported in September 2023 that 74% of the 41 million deaths worldwide every year result from non-communicable diseases (NCDs) or chronic diseases. Thus, the surge in chronic diseases is likely to boost the exocrine pancreatic insufficiency market. Driver of Exocrine Pancreatic Insufficiency Market: Growth Propelled by Surging Diabetes Cases

Which Companies Are Leading in the Exocrine Pancreatic Insufficiency Market?
Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan PLC, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma PLC, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc., Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics

What Are the Major Trends Shaping the Exocrine Pancreatic Insufficiency Market?
Leading corporations in the exocrine pancreatic insufficiency market, such as Nestlé Health Science, are establishing patient advocacy factions for detailed nutritional guidance and backing. The objective of these projects is to enhance the understanding, tuition, and handling of the matter amongst those affected. Comprehensive nutritional guidance adopts a comprehensive method that customizes diet advice based on personal requirements, health ailments, and way of life. The focus is on education, meal planning, and enduring practices to encourage comprehensive well-being. In an example from June 2024, the Switzerland-based company, Nestlé Health Science, introduced a GLP-1 diet assistance platform. This platform from Nestlé Health Science provides customized dietary resources and professional advice for those using GLP-1 medications, projecting on muscle retention, gut health, and overall fitness. Its mission is to facilitate users' weight management journey, understanding unique dietary needs, and promoting communal backing.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

What Are the Top Revenue-Generating Geographies in the Exocrine Pancreatic Insufficiency Market?
North America was the largest region in the exocrine pancreatic insufficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Exocrine Pancreatic Insufficiency Market?
2. What is the CAGR expected in the Exocrine Pancreatic Insufficiency Market?
3. What Are the Key Innovations Transforming the Exocrine Pancreatic Insufficiency Industry?
4. Which Region Is Leading the Exocrine Pancreatic Insufficiency Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.